KRAS G12C clinical trials at UCSF

1 research study open to eligible people

A KRAS G12C mutation is an alteration in a cancer-related gene. UCSF is conducting tests with a drug named FMC-376 on patients with this gene change. The purpose is to evaluate the drug's effects on advanced solid tumors.

Showing trials for

  • FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

    open to eligible people ages 18 years and up

    The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.

    San Francisco 5391959, California 5332921 and other locations

Our lead scientists for KRAS G12C research studies include .

Last updated: